Direkt zum Inhalt
Merck

The focal adhesion scaffold protein Hic-5 regulates vimentin organization in fibroblasts.

Molecular biology of the cell (2019-10-24)
Rishel B Vohnoutka, Anushree C Gulvady, Gregory Goreczny, Kyle Alpha, Samuel K Handelman, Jonathan Z Sexton, Christopher E Turner
ZUSAMMENFASSUNG

Focal adhesion (FA)-stimulated reorganization of the F-actin cytoskeleton regulates cellular size, shape, and mechanical properties. However, FA cross-talk with the intermediate filament cytoskeleton is poorly understood. Genetic ablation of the FA-associated scaffold protein Hic-5 in mouse cancer-associated fibroblasts (CAFs) promoted a dramatic collapse of the vimentin network, which was rescued following EGFP-Hic-5 expression. Vimentin collapse correlated with a loss of detergent-soluble vimentin filament precursors and decreased vimentin S72/S82 phosphorylation. Additionally, fluorescence recovery after photobleaching analysis indicated impaired vimentin dynamics. Microtubule (MT)-associated EB1 tracking and Western blotting of MT posttranslational modifications indicated no change in MT dynamics that could explain the vimentin collapse. However, pharmacological inhibition of the RhoGTPase Cdc42 in Hic-5 knockout CAFs rescued the vimentin collapse, while pan-formin inhibition with SMIFH2 promoted vimentin collapse in Hic-5 heterozygous CAFs. Our results reveal novel regulation of vimentin organization/dynamics by the FA scaffold protein Hic-5 via modulation of RhoGTPases and downstream formin activity.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Monoklonaler Anti-α-Tubulin-Antikörper in Maus hergestellte Antikörper, clone DM1A, ascites fluid
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Sigma-Aldrich
Monoklonales Anti-Tubulin, acetyliert in Maus hergestellte Antikörper, clone 6-11B-1, ascites fluid
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Sigma-Aldrich
MISSION® esiRNA, targeting human PXN (1)
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Sigma-Aldrich
MISSION® esiRNA, targeting human TGFB1I1
Preise und Verfügbarkeit sind derzeit nicht verfügbar.